WOBURN, Mass. and NEW YORK, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Abpro Corporation ("Abpro"), a biotech company with the mission of improving the lives of mankind facing severe and life-threatening ...
WOBURN, Mass. and NEW YORK, Nov. 13, 2024 /PRNewswire/ -- Abpro Corporation, a biotechnology company with the mission of improving the lives of those facing severe and life-threatening diseases with ...
BURLINGTON, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Abpro Corporation (Nasdaq: ABP) (“Abpro”) and Celltrion, Inc. (“Celltrion”) today announced that they will present new preclinical data for ...
WOBURN, Mass. & NEW YORK--(BUSINESS WIRE)--Abpro Corporation (“Abpro”), a biotechnology company with the mission of improving the lives of those facing severe and life-threatening diseases with ...
The Nature Index tracks primary research articles from 145 natural-science and health-science journals, chosen based on reputation by an independent group of researchers. The Nature Index provides ...
Abpro Holdings, Inc. (NASDAQ:ABP), a leading biopharmaceutical company, has recently disclosed several significant post-merger activities through an 8-K filing with the United States Securities and ...
The positions in the table below reflect the Abpro Corporation's position overall, domestically, within their sector, and in various subject areas based on their Share. Each position links to the ...
Abpro Expected to Begin Trading on Nasdaq on Thursday, November 14, 2024, Under the Tickers "ABP" and "ABPWW" WOBURN, Mass. and NEW YORK, Nov. 13, 2024 /PRNewswire/ -- Abpro Corporation, a ...
Abpro is a biotechnology company specializing in the development of next-generation antibody therapies intended to improve the lives of those with life-threatening diseases. The transaction values ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results